Interim 18f-fdg pet suVmax reduction is superior to visual analysis in predicting outcome early in hodgkin Lymphoma Patients

Journal of Nuclear Medicine

Volumn 55, Issue 4, 2014, Pages 569-573

  Rossi, Cédric ^a   Kanoun, Salim ^b   Berriolo Riedinger, Alina ^b   Dygai Cochet, Inna ^b   Humbert, Olivier ^b   Legouge, Caroline ^a   Chrétien, Marie Lorraine ^a   Bastie, Jean Noel ^a   Brunotte, François ^b   Casasnovas, René Olivier ^a  

^a HÔPITAL DU BOCAGE   (France)

^b CENTRE GEORGES FRANÇOIS LECLERC   (France)

Author keywords

5 point scale; Hodgkin lymphoma; Interim PET

Indexed keywords

ANTHRACYCLINE DERIVATIVE; FLUORODEOXYGLUCOSE F 18; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADOLESCENT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CONTROLLED STUDY; FEMALE; HODGKIN DISEASE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MAXIMUM STANDARDIZED UPTAKE VALUE; MEASUREMENT ACCURACY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; RADIOLOGICAL PARAMETERS; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE; VISUAL DISCRIMINATION; 18F-FDG PET; 5-POINT SCALE; ADULT; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; IMAGE PROCESSING; INTERIM PET; METHODOLOGY; MIDDLE AGED; PROGNOSIS; SCINTISCANNING; SURVIVAL; SUVMAX; TREATMENT OUTCOME; YOUNG ADULT;

18F-FDG PET; 5-POINT SCALE; HODGKIN LYMPHOMA; INTERIM PET; SUVMAX;

ADOLESCENT; ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; ROC CURVE; SURVIVAL ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84899966595     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.130609     Document Type: Article

References (19)

1. Hutchings M, Barrington SF. PET/CT for therapy response assessment in lymphoma. J Nucl Med. 2009;50(suppl):21S-30S.
2. Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107:52-59.
3. Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica. 2006;91:475-481.
4. Zijlstra JM, Boellaard R, Hoekstra OS. Interim positron emission tomography scan in multi-center studies: optimization of visual and quantitative assessments. Leuk Lymphoma. 2009;50:1748-1749.
5. Zinzani PL, Tani M, Fanti S, et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. Ann Oncol. 2006;17:1296-1300.
6. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-Dglucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25:3746-3752.
7. Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol. 2009;27:1906-1914.
8. Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET scan in lymphoma. Leuk Lymphoma. 2009;50:1257-1260.
9. Horning SJ, Juweid ME, Schöder H, et al. Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 Study. Blood. 2010;115:775-777.
10. Itti E, Meignan M, Berriolo-Riedinger A, et al. An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and DSUVmax. Eur J Nucl Med Mol Imaging. 2013;40:1312-1320.
11. Lin C, Itti E, Haioun C, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med. 2007;48:1626-1632.
12. Casasnovas R-O, Meignan M, Berriolo-Riedinger A, et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood. 2011;118:37-43.
13. Swerdlow S, Campo E, Harris N. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer; 2008.
14. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579-586.
15. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39:561-577.
16. Biggi A, Gallamini A, Chauvie S, et al. International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J Nucl Med. 2013;54:683-690.
17. Canellos GP. Residual mass in lymphoma may not be residual disease. J Clin Oncol. 1988;6:931-933.
18. Itti E, Juweid ME, Haioun C, et al. Improvement of early 18F-FDG PET interpretation in diffuse large B-cell lymphoma: importance of the reference background. J Nucl Med. 2010;51:1857-1862.
19. Casasnovas R-O, Meignan M, Berriolo-Riedinger A, et al. Early interim PET scans in diffuse large B-cell lymphoma: can there be consensus about standardized reporting, and can PET scans guide therapy choices? Curr Hematol Malig Rep. 2012;7:193-199.